Product Description
KSHN001126 was developed as a steroidal SERD by exploring multiple ER-protein conformations and identifying a subpocket around the core hydrophobic site where the molecule can be extended. KSHN001126 perfectly occupies both the original and subpocket formed by the pocket breathing phenomenon. Being steroidal SERD, KSHN001126 has the potential to be efficacious in the mutant/non-mutant conditions. KSHN001126 was studied in MCF-7 cells in- vitro to understand ER localization confirming cytosolic abundance and ERα immobilization. (Sourced from: https://aacrjournals.org/cancerres/article/83/7_Supplement/1616/722143/Abstract-1616-Preclinical-characterization-of)
Mechanisms of Action: ER Antagonist
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shivanka Research, LLC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: India, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CE-24-02 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-12-01 |